InflaRx N.V. (HAM:IF0) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard Brudnick Other companies: Scholar Rock Holding Corporation (Director · Since at least Apr 6, 2023); Prime Medicine, Inc. (Chief Business Officer · Oct 19, 2022 – May 20, 2025 · Past); VolitionRx Limited (Director · Mar 25, 2021 – Jan 12, 2023 · Past); Codiak BioSciences Inc (See Remarks · Oct 13, 2020 – Feb 16, 2022 · Past); Bioverativ Inc (EVP, Business Development · Dec 22, 2016 – Mar 8, 2018 · Past) | Board Member · Since at least Mar 18, 2026 |
| Anthony S Gibney Other companies: Aura Biosciences, Inc. (See Remarks · Since at least May 13, 2025) | Director · Since at least Mar 18, 2026 |
| Andreas Kronbichler | Director · Since at least Nov 3, 2026 |
| Christian Schmid | VP, Head of Legal Affairs & General Counsel · Since at least Nov 5, 2026 |
| Daniel Vetter | Senior Director, Head of IT · Since at least Nov 5, 2026 |
| David Jayne | Board Member · Since at least Nov 3, 2026 |
| Derval O’Carroll | Senior Vice President, Global Head of Regulatory Affairs & Compliance · Since at least Mar 18, 2026 |
| Gabriela Alperovich | Senior Vice President & Global Head of Clinical Development · Since Oct 1, 2026 |
| Hege Hellstrom | Board Member · Since at least Nov 5, 2026 |
| Igor Orshanskiy | Senior Director, Head of Business Development · Since at least Nov 5, 2026 |
| Jan Medina | Vice President, Head of Investor Relations · Since at least Nov 3, 2026 |
| Jonathan Barratt | Board Member · Since at least Nov 3, 2026 |
| Jürgen Floege | Board Member · Since at least Nov 3, 2026 |
| Kirsten Cremering | Senior Director, Head of Quality Assurance · Since at least Nov 5, 2026 |
| Kofi Boaten | VP, Head of Supply Quality & Clinical Trial Supplies · Since at least Nov 5, 2026 |
| Maria Habel | VP, Head of preclinical R&D and QC · Since at least Nov 5, 2026 |
| Mark Kubler | Director · Since at least Mar 18, 2026 |
| med. Bernhard Hellmich | Board Member · Since at least Nov 3, 2026 |
| Ming-hui ZHAO | Director · Since at least Nov 3, 2026 |
| Nicolas Fulpius | Chairman of the Board · Since at least Mar 18, 2026 |
| Niels C. Riedemann | Chief Executive Officer, Director · Since at least Mar 18, 2026 |
| Peter A. Merkel | Board Member · Since at least Nov 3, 2026 |
| Peter Hurt | Senior Director, Head of Drug Safety and Pharmacovigilance · Since at least Nov 5, 2026 |
| Petra Eßer | VP, Head of Finance and Controlling · Since at least Nov 5, 2026 |
| Renfeng Guo | Chief Scientific Officer, Director · Since at least Mar 18, 2026 |
| Thomas Taapken | Chief Financial Officer · Since at least Aug 6, 2026 |
| Tony Gibney | Board Member, Head of Audit Committee · Since at least Nov 4, 2026 |